Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News AHA 2017

More Support for TMVR After Failed Mitral Bioprostheses

Yael L. Maxwell

November 23, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Case Presentation 6: BTK Intervention

Presenter: Sergey A. Abugov, Juan F. Granada, Zaza Kavteladze

October 29, 2017

Presentation TCT 2017

Editorial Comment

Presenter: Sergey A. Abugov, Juan F. Granada, Susheel K. Kodali

October 29, 2017

Presentation TCT 2017

Case Presentation 5: TAVR

Presenter: Sergey A. Abugov, Juan F. Granada, Alexey Protopopov

October 29, 2017

Presentation TCT 2017

Tricuspid Valve Interventions: Patient Selection, Devices, and Predictions

Presenter: Antonio Colombo, Samir R. Kapadia, Azeem Latib

October 29, 2017

Presentation TCT 2017

Mitral Valve Interventions: MitraClip, Annular Treatments, and Valves Where Will We Be in 5 Years? In 10 Years?

Presenter: Antonio Colombo, Azeem Latib, Jason H. Rogers

October 29, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

Advertisement

More Support for TMVR After Failed Mitral Bioprostheses

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

The PARTNER 3 Low-risk Trial

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Case Presentation 6: BTK Intervention

Editorial Comment

Case Presentation 5: TAVR

Tricuspid Valve Interventions: Patient Selection, Devices, and Predictions

Mitral Valve Interventions: MitraClip, Annular Treatments, and Valves Where Will We Be in 5 Years? In 10 Years?

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content